Iñigo Angulo-Barturen

发表

Chemical genetics of Plasmodium falciparum

Anang A. Shelat, David S. Roos, John S. Lazo, 2010, Nature.

Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia.

T. Gumbo, Iñigo Angulo-Barturen, Santiago Ferrer-Bazaga, 2015, The Journal of infectious diseases.

A novel class of fast‐acting antimalarial agents: Substituted 15‐membered azalides

F. Gamo, S. Alihodžić, Mirjana Bukvić, 2020, British journal of pharmacology.

Discovery of a Potent and Speci fi c M . tuberculosis Leucyl-tRNA Synthetase Inhibitor : ( S ) ‐ 3-( Aminomethyl )

David Barros, J. Plattner, Esther Pérez-Herrán, 2017 .

Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656).

David Barros, J. Plattner, Esther Pérez-Herrán, 2017, Journal of medicinal chemistry.

4‐Substituted Thioquinolines and Thiazoloquinolines: Potent, Selective, and Tween‐80 in vitro Dependent Families of Antitubercular Agents with Moderate in vivo Activity

David Barros, Lluís Ballell, Jaime. Escribano, 2011, ChemMedChem.

Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity

P. Rathod, John White, M. Phillips, 2016, Journal of medicinal chemistry.

Anti-malarial Activity in the Mouse Model Dihydroorotate Dehydrogenase with Plasmodium falciparum Novel Inhibitors of Molecular Bases of Disease :

Margaret A. Phillips, Elizabeth J. Goldsmith, Dyann F. Wirth, 2010 .

A novel multiple-stage antimalarial agent that inhibits protein synthesis

David W. Gray, E. Winzeler, S. Meister, 2015, Nature.

Study of Tissue-Specific Reactive Oxygen Species Formation by Cell Membrane Microarrays for the Characterization of Bioactive Compounds

N. Nieto, T. Morera-Herreras, A. González-Coloma, 2021, Membranes.

A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery

David M. Wilson, F. Gamo, J. Garcia-Bustos, 2013, PloS one.

Mycobacterium tuberculosis Gyrase Inhibitors as a New Class of Antitubercular Drugs

J. Lavandera, David Barros, Lluís Ballell, 2015, Antimicrobial Agents and Chemotherapy.

A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria.

David M. Shackleford, R. Price, P. Rathod, 2016, ACS infectious diseases.

Synthesis and structure-activity relationships of novel benzoxaboroles as a new class of antimalarial agents.

J. Gut, P. Rosenthal, F. Gamo, 2011, Bioorganic & medicinal chemistry letters.

Improved Murine Model of Malaria Using Plasmodium falciparum Competent Strains and Non-Myelodepleted NOD-scid IL2Rγnull Mice Engrafted with Human Erythrocytes

L. Shultz, M. Jiménez-Díaz, Iñigo Angulo-Barturen, 2009, Antimicrobial Agents and Chemotherapy.

Synthesis and profiling of benzylmorpholine 1,2,4,5-tetraoxane analogue N205: Towards tetraoxane scaffolds with potential for single dose cure of malaria.

David M. Shackleford, Brice Campo, M. Belén, 2018, Bioorganic & medicinal chemistry.

A potent series targeting the malarial cGMP-dependent protein kinase clears infection and blocks transmission

S. Croft, T. Bousema, F. Gamo, 2017, Nature Communications.

Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life Cycle.

E. Winzeler, S. Meister, K. Chibale, 2016, Journal of medicinal chemistry.

Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development

J. McCarthy, D. Leroy, P. O’Rourke, 2016, Antimicrobial Agents and Chemotherapy.

A Novel Pyrazolopyridine with in Vivo Activity in Plasmodium berghei- and Plasmodium falciparum-Infected Mouse Models from Structure-Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines.

E. Winzeler, S. Meister, K. Chibale, 2015, Journal of medicinal chemistry.

Carbamoyl Triazoles, Known Serine Protease Inhibitors, Are a Potent New Class of Antimalarials.

Laura M Sanz, L. Ballell-Pages, M. Blackman, 2015, Journal of Medicinal Chemistry.

Humanised models of infection in the evaluation of anti-malarial drugs.

Iñigo Angulo-Barturen, S. Ferrer, 2013, Drug discovery today. Technologies.

The Discovery of Novel Antimalarial Aminoxadiazoles as a Promising Nonendoperoxide Scaffold.

David M. Wilson, G. Drewes, P. Bamborough, 2017, Journal of medicinal chemistry.

Case Study of Small Molecules As Antimalarials: 2-Amino-1-phenylethanol (APE) Derivatives.

F. Gamo, J. Vidal, Gonzalo Colmenarejo, 2014, ACS medicinal chemistry letters.

A Plasmodium berghei sporozoite-based vaccination platform against human malaria

Joana C. Silva, S. Bhatia, M. Mota, 2018, npj Vaccines.

Discovery and Characterization of Potent, Efficacious, Orally Available Antimalarial Plasmepsin X Inhibitors and Preclinical Safety Assessment of UCB7362

Richard D. Taylor, D. Goldberg, A. Cowman, 2022, Journal of medicinal chemistry.

Identification of Fast-Acting 2,6-Disubstituted Imidazopyridines That Are Efficacious in the in Vivo Humanized Plasmodium falciparum NODscidIL2Rγ null Mouse Model of Malaria.

K. Chibale, Dale Taylor, K. Wicht, 2018, Journal of medicinal chemistry.

Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis.

I. Orme, T. Dick, S. Franzblau, 2012, Tuberculosis.

Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis

Juan A. Bueren-Calabuig, Andrei V. Pisliakov, David W. Gray, 2019, Proceedings of the National Academy of Sciences.

Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials

E. Winzeler, S. Meister, S. Norval, 2016, Journal of medicinal chemistry.

Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.

David M. Shackleford, Francisco-Javier Gamo, Xiaoyi Deng, 2011, Journal of medicinal chemistry.

Combinations of β-Lactam Antibiotics Currently in Clinical Trials Are Efficacious in a DHP-I-Deficient Mouse Model of Tuberculosis Infection

A. Diacon, J. Lelièvre, J. Mckinney, 2015, Antimicrobial Agents and Chemotherapy.

Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum

Sandhya Kortagere, Thomas D. Otto, Vicky M. Avery, 2014, Nature Communications.

UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria

R. Price, K. Chibale, Dale Taylor, 2018, Antimicrobial Agents and Chemotherapy.

Enzyme Therapy: Current Challenges and Future Perspectives

A. Gomez-Gonzalez, A. Acera, E. Astigarraga, 2021, International journal of molecular sciences.

Optimized Pyridazinone Nutrient Channel Inhibitors Are Potent and Specific Antimalarial Leads

J. Burrows, S. T. Nguyen, M. Jiménez-Díaz, 2022, Molecular Pharmacology.

Exploration of 4(1H)-pyridones as a novel family of potent antimalarial inhibitors of the plasmodial cytochrome bc1.

F. Gamo, E. Herreros, Iñigo Angulo-Barturen, 2012, Future medicinal chemistry.

A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance

David M. Shackleford, R. Price, D. Fidock, 2017, Nature Communications.

A Murine Model of falciparum-Malaria by In Vivo Selection of Competent Strains in Non-Myelodepleted Mice Engrafted with Human Erythrocytes

P. Rosenthal, J. Regadera, D. Pompliano, 2008, PloS one.

A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria

Farah El Mazouni, T. Laird, P. Rathod, 2015, Science Translational Medicine.

Animal models of efficacy to accelerate drug discovery in malaria

M. Jiménez-Díaz, Iñigo Angulo-Barturen, Elena Fernández‐Álvaro, 2013, Parasitology.

Antimalarial pantothenamide metabolites target acetyl–coenzyme A biosynthesis in Plasmodium falciparum

M. Llinás, P. Jansen, K. Dechering, 2019, Science Translational Medicine.

Repositioning: the fast track to new anti-malarial medicines?

Michele Connelly, R Kiplin Guy, Timothy Wells, 2014, Malaria Journal.

Quinolone-3-Diarylethers: A New Class of Antimalarial Drug

Yuexin Li, David M. Shackleford, Susan A Charman, 2013, Science Translational Medicine.

(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium

Hongshen Ma, Zheng Wang, Jeremy Horst, 2014, Proceedings of the National Academy of Sciences.

Quinolone-3-Diarylethers : A new class of drugs for a new era of malaria eradication

David M. Shackleford, R. Price, M. Mather, 2014 .

Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase

David M. Shackleford, G. Drewes, M. Bantscheff, 2017, Science Translational Medicine.

Identification of KasA as the cellular target of an anti-tubercular scaffold

Robert H Bates, N. Loman, G. Drewes, 2016, Nature Communications.

Aminoindoles, a Novel Scaffold with Potent Activity against Plasmodium falciparum

Bradley I. Coleman, R. Barker, D. Wirth, 2011, Antimicrobial Agents and Chemotherapy.

Discovery and Preclinical Pharmacology of INE963, a Potent and Fast-Acting Blood-Stage Antimalarial with a High Barrier to Resistance and Potential for Single-Dose Cures in Uncomplicated Malaria

F. Gamo, E. Fang, Yen-Liang Chen, 2022, Journal of medicinal chemistry.

The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance

R. Price, P. Rosenthal, D. Fidock, 2021, Science Translational Medicine.

Immunoliposome-mediated drug delivery to Plasmodium-infected and non-infected red blood cells as a dual therapeutic/prophylactic antimalarial strategy.

P. Urban, M. Busquets, X. Fernàndez-Busquets, 2015, Journal of controlled release : official journal of the Controlled Release Society.

THPP target assignment reveals EchA6 as an essential fatty acid shuttle in mycobacteria

G. Drewes, M. Bantscheff, G. Besra, 2016, Nature Microbiology.

Pulmonary Mycobacterium bovis BCG Vaccination Confers Dose-Dependent Superior Protection Compared to That of Subcutaneous Vaccination

E. Gormley, Carlos Martín, N. Aguiló, 2014, Clinical and Vaccine Immunology.

Subcutaneous Vaccination Superior Protection Compared to That of Vaccination Confers Dose-Dependent Pulmonary Mycobacterium bovis BCG

E. Gormley, Carlos Martín, Esther Pérez-Herrán, 2014 .

Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA.

Hongfang Yang, William McDowell, Paolo A Centrella, 2014, Journal of medicinal chemistry.

Fast Standardized Therapeutic-Efficacy Assay for Drug Discovery against Tuberculosis

P. Cardona, Iñigo Angulo-Barturen, J. Rullas, 2010, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis

S. Croft, A. Voak, K. Seifert, 2021, PLoS neglected tropical diseases.

Tetrahydropyrazolo[1,5-a]Pyrimidine-3-Carboxamide and N-Benzyl-6′,7′-Dihydrospiro[Piperidine-4,4′-Thieno[3,2-c]Pyran] Analogues with Bactericidal Efficacy against Mycobacterium tuberculosis Targeting MmpL3

N. Loman, C. Constantinidou, M. Pallen, 2013, PloS one.

Design, synthesis, and evaluation of new thiadiazole-based direct inhibitors of enoyl acyl carrier protein reductase (InhA) for the treatment of tuberculosis.

S. Turk, David Barros, L. Ballell-Pages, 2015, Journal of medicinal chemistry.

N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds.

D. Fidock, F. Gamo, A. Srivastava, 2014, Journal of medicinal chemistry.

Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.

D. Wirth, F. Gamo, Pavithra Viswanath, 2014, Journal of medicinal chemistry.

Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA Synthetase

Christopher B. Cooper, Lisa K. Woolhiser, J. Sacchettini, 2016, Antimicrobial Agents and Chemotherapy.

Cyclopropyl Carboxamides, a Chemically Novel Class of Antimalarial Agents Identified in a Phenotypic Screen

Jeremy N. Burrows, Benigno Crespo, Francisco-Javier Gamo, 2011, Antimicrobial Agents and Chemotherapy.

Optimization of Potent Inhibitors of P. falciparum Dihydroorotate Dehydrogenase for the Treatment of Malaria.

R. Barker, B. Muñoz, J. Cortese, 2011, ACS medicinal chemistry letters.

Quantitative measurement of Plasmodium‐infected erythrocytes in murine models of malaria by flow cytometry using bidimensional assessment of SYTO‐16 fluorescence

M. Jiménez-Díaz, Iñigo Angulo-Barturen, D. Gargallo‐Viola, 2009, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor

J. Sacchettini, E. Alvarez, J. Lavandera, 2016, EBioMedicine.

Erratum: Antimalarial pantothenamide metabolites target acetyl-coenzyme A biosynthesis in Plasmodium falciparum (Science Translational Medicine DOI: 10.1126/scitranslmed.aas9917)

M. Llinás, P. Jansen, K. Dechering, 2021 .

Histone Methyltransferase Inhibitors Are Orally Bioavailable, Fast-Acting Molecules with Activity against Different Species Causing Malaria in Humans

N. A. Malmquist, R. Sinden, F. Gamo, 2014, Antimicrobial Agents and Chemotherapy.

Determination of the Pharmacokinetics and Pharmacodynamics of Isoniazid, Rifampicin, Pyrazinamide and Ethambutol in a Cross-Over Cynomolgus Macaque Model of Mycobacterium tuberculosis Infection

F. Gleeson, J. Vaquero, L. Alameda, 2022, Pharmaceutics.

Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183

P. Rosenthal, M. Llinás, D. Fidock, 2021, bioRxiv.

Predicting Optimal Antimalarial Drug Combinations from a Standardized Plasmodium falciparum Humanized Mouse Model

D. Leroy, M. Jiménez-Díaz, Iñigo Angulo-Barturen, 2023, Antimicrobial agents and chemotherapy.

Chemoprotective Antimalarial Activity of P218 against Plasmodium falciparum: A Randomized, Placebo-Controlled Volunteer Infection Study

A. Rosanas-Urgell, Mohammed H. Cherkaoui-Rbati, Iñigo Angulo-Barturen, 2021, The American journal of tropical medicine and hygiene.

Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose–Efficacy Modeling

R. Price, D. Fidock, R. Sinden, 2016, PLoS medicine.

Repositioning: the fast track to new anti-malarial medicines?

R. Guy, Pavithra Viswanath, V. Avery, 2014, Malaria Journal.

Feasibility of Flow Cytometry for Measurements of Plasmodium falciparum Parasite Burden in Studies in Areas of Malaria Endemicity by Use of Bidimensional Assessment of YOYO-1 and Autofluorescence

J. Sacarlal, J. Aponte, P. Alonso, 2011, Journal of Clinical Microbiology.

Novel Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase with Anti-malarial Activity in the Mouse Model*

Bradley I. Coleman, E. Goldsmith, R. Barker, 2010, The Journal of Biological Chemistry.

Improvement of detection specificity of Plasmodium‐infected murine erythrocytes by flow cytometry using autofluorescence and YOYO‐1

M. Jiménez-Díaz, Iñigo Angulo-Barturen, D. Gargallo‐Viola, 2005, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

The multistate tuberculosis pharmacometric model: a semi-mechanistic pharmacokinetic-pharmacodynamic model for studying drug effects in an acute tuberculosis mouse model

L. Alameda, Iñigo Angulo-Barturen, S. Ferrer, 2017, Journal of Pharmacokinetics and Pharmacodynamics.

Identifying rapidly parasiticidal anti-malarial drugs using a simple and reliable in vitro parasite viability fast assay

F. Gamo, Virginia Franco, Benigno Crespo, 2015, Malaria Journal.

Lead optimization of a pyrrole-based dihydroorotate dehydrogenase inhibitor series for the treatment of Malaria.

David M. Shackleford, P. Rathod, John White, 2020, Journal of medicinal chemistry.

Erratum: (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium (Proceedings of the National Academy of Sciences of the United States of America (2014) 111 (E5455-E5462) 1 DOI: 10.1073/pnas.1414221111)

Anang A. Shelat, Zheng Wang, Jeremy A. Horst, 2015 .

Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis

E. Winzeler, S. Meister, J. Rayner, 2016, Nature.

Synthesis and Structure-Activity Relationships of the Novel Antimalarials 5-Pyridinyl-4(1 H)-Pyridones.

J. Burrows, E. Herreros, Iñigo Angulo-Barturen, 2018, Journal of medicinal chemistry.

Potent Antimalarials with Development Potential Identified by Structure-Guided Computational Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series.

David M. Shackleford, E. Winzeler, P. Rathod, 2021, Journal of medicinal chemistry.

Macrocyclic Peptidomimetic Plasmepsin X Inhibitors with Potent In Vitro and In Vivo Antimalarial Activity.

A. Jirgensons, C. Withers-Martinez, F. Hackett, 2023, Journal of medicinal chemistry.

University of Birmingham Identification of KasA as the cellular target of an anti-tubercular scaffold

Robert H Bates, N. Loman, G. Drewes, 2016 .

A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria

Farah El Mazouni, T. Laird, P. Rathod, 2015, Science Translational Medicine.

Immunoliposome-mediated drug delivery to Plasmodium-infected and non-infected red blood cells as a dual therapeutic/prophylactic antimalarial strategy.

P. Urban, M. Busquets, X. Fernàndez-Busquets, 2015, Journal of controlled release : official journal of the Controlled Release Society.